Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00272558

Enrollment

Registered

2006-01-06

Start date

2004-09-30

Completion date

2009-09-30

Last updated

2009-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Pleural Mesothelioma

Keywords

Malignant Pleural Mesothelioma, Chemotherapy

Brief summary

The purpose is to evaluate the activity and feasibility of a two drug regimen which is partly orally and partly intravenous in advanced pleural mesothelioma.

Detailed description

Chemotherapy with carboplatin i.v. day one in each cycle Vinorelbine i.v. day one, and orally day 8 in each cycle, repeat new cycle every 3 weeks. Total of 6 cycles. Endpoint is response rate, secondary endpoints survival and toxicity.

Interventions

DRUGCarboplatin and Vinorelbine

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Histologically verified malignant pleural Mesothelioma * Age above 18 years * Performance status 0-2

Exclusion criteria

* No previous chemotherapy * Normal renal, liver and bone marrow function

Design outcomes

Primary

Measure	Time frame
Response	—

Secondary

Measure	Time frame
Survival	—
Feasibility	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026